Rigel Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
Notes Tables
Notes Details

SPONSORED RESEARCH AND LICENSE AGREEMENTS (Details)

v3.3.1.900

SPONSORED RESEARCH AND LICENSE AGREEMENTS (Details) - USD ($)	1 Months Ended		12 Months Ended
	Sep. 30, 2015	Mar. 31, 2015	Dec. 31, 2015
Collaborative Arrangement
Collaborations
Maximum amount of contingent payments receivable			$ 533,600,000
Specified Development Events \| Collaborative Arrangement
Collaborations
Maximum amount of contingent payments receivable			150,500,000
Specified Regulatory Events \| Collaborative Arrangement
Collaborations
Maximum amount of contingent payments receivable			345,600,000
Specified Product Launch Events \| Collaborative Arrangement
Collaborations
Maximum amount of contingent payments receivable			37,500,000
Bristol-Myers Squibb Company
Collaborations
Upfront fee received		$ 30,000,000
Deferred revenue related to upfront payment		$ 30,000,000	13,400,000
Revenue recognized			16,600,000
Bristol-Myers Squibb Company \| Research Activities
Collaborations
Revenue recognized			822,000
Bristol-Myers Squibb Company \| Minimum
Collaborations
Contingent payments			309,000,000
Aclaris
Collaborations
Upfront fee received	$ 8,000,000
Contingent payments			80,000,000
Revenue recognized			$ 8,000,000

- Definition

Represents the amount of deferred revenue as of balance sheet date related to upfront payment under the collaborative and licensing agreement.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementDeferredRevenueRelatedToUpfrontPayment
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the maximum amount of pre-specified contingent payments receivable under the collaborative and licensing agreement.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementMaximumAmountOfContingentPaymentReceivable
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the revenue recognized during the period under the terms of sponsored research and license agreements.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementRevenueRecognized
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the amount of upfront fees received during the period under the terms of collaborative and licensing agreement.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementUpfrontFeeReceived
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the additional contingent payments by BMS.

+ References

No definition available.

+ Details

Name:	rigl_ContingentPaymentsUnderAgreement
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_SpecifiedDevelopmentEventsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_SpecifiedRegulatoryEventsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_SpecifiedProductLaunchEventsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=rigl_BristolMyersSquibbCompanyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_ResearchActivitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=rigl_AclarisTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: